Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist

J Psychopharmacol. 2002 Jun;16(2):191. doi: 10.1177/026988110201600212.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / complications
  • Breast Neoplasms / psychology
  • Female
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Middle Aged
  • Quinolizines / adverse effects
  • Quinolizines / therapeutic use
  • Receptors, Serotonin / drug effects*
  • Receptors, Serotonin, 5-HT3
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin Antagonists / adverse effects*
  • Serotonin Syndrome / psychology*
  • Sertraline / adverse effects
  • Sertraline / therapeutic use

Substances

  • Antineoplastic Agents
  • Indoles
  • Quinolizines
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT3
  • Serotonin Antagonists
  • Serotonin Uptake Inhibitors
  • dolasetron
  • Sertraline